FDA Grants Accelerated Approval to Neladalkib for ALK-Positive NSCLC
On November 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to neladalkib (Nelkarmi), a kinase inhibitor, for adults with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting:
One prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib
Two or more prior ALK TKIs and platinum-based chemotherapy.
ALKOVE-1
Efficacy was evaluated in ALKOVE-1 (ClinicalTrials.gov identifier NCT05384626), a multicenter, single-arm, open-label, multi-cohort trial in 67 patients who received one prior ALK TKI consisting of alectinib in the metastatic setting and 155 patients who received two or more prior ALK TKIs and platinum-based chemotherapy.
The major efficacy outcome measures were confirmed overall response rate and duration of response according to Response Evaluation Criteria in Solid Tumors version 1.1 as assessed by blinded independent central review. Among patients who received one prior ALK TKI consisting of alectinib (n = 67), overall response rate was 49% (95% confidence interval [CI] = 37%–62%); 76% of responding patients had a duration of response of ≥ 6 months and 52% had a duration of response of ≥ 12 months. Among patients who received two or more prior ALK TKIs and platinum-based chemotherapy (n = 155), the overall response rate was 32% (95% CI = 24%–40%); 69% of responding patients had a duration of response of ≥ 6 months and 51% had a duration of response of ≥ 12 months.
The prescribing information for neladalkib includes warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. The most common adverse reactions (occurring in ≥ 20% of patients) were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue.
Recommended Dosage
The recommended neladalkib dose is 150 mg orally once daily with or without food taken at the same time every day until disease progression or unacceptable toxicity.
This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.
This application was granted Priority Review. Neladalkib received Breakthrough Therapy designation and Orphan Drug designation.